SummaryThis article recapitulates the evidence on the interaction between Wnt/β-catenin and phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin complex 1 pathways in cancer, with a primary focus on intestinal tumorigenesis, and describes the main molecular mechanisms underlying this crosstalk and impact on the resistance to colorectal cancer target therapies.

Colorectal cancer (CRC) is the third most common malignancy in terms of both incidence and mortality worldwide.[@bib1] Although surgery combined with standard chemotherapy is effective for early stages, metastatic CRC often is resistant to conventional treatments.

The Wnt/β-catenin pathway and the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) axis frequently are deregulated in CRC, therefore representing an attractive target for chemoprevention and treatment.[@bib2]^,^[@bib3]

The Wnt/β-catenin pathway, also known as the canonical Wnt pathway, controls the self-renewal of intestinal stem cells and is crucial for preserving intestinal homeostasis.[@bib4]^,^[@bib5] However, sustained Wnt/β-catenin signaling activation triggers hyperproliferation and oncogenic transformation of intestinal epithelial cells, leading to CRC onset.[@bib4]

The PI3K/AKT/mTOR pathway regulates multiple cellular events including cell growth, proliferation, metabolism, protein and lipid synthesis, and autophagy.[@bib6] Moreover, the aberrant activation of the PI3K/AKT/mTOR pathway often has been reported in cancer settings.[@bib6]

A close connection between Wnt/β-catenin and PI3K/AKT/mTOR signaling has been described in CRC. Indeed, these pathways share common effectors and are able to mutually regulate each other.

Over the years, numerous inhibitors of Wnt/β-catenin and PI3K/mTOR complex 1 (mTORC1) pathways have been developed and tested against CRC. These targeted therapies have shown clinical effectiveness in the treatment of advanced CRC, although the long-term effects frequently fail owing to the acquisition of resistance mechanisms.[@bib7]^,^[@bib8] In particular, Wnt/β-catenin pathway inhibition has been associated with the up-regulation of the PI3K/AKT/mTORC1 pathway and, similarly, blocking the PI3K/AKT/mTORC1 cascade results in Wnt/β-catenin signaling hyperactivation as a compensatory mechanism.

This review comprehensively discusses the literature concerning the mechanisms linking the Wnt/β-catenin and PI3K/AKT/mTORC1 pathways in CRC development and elucidates the biological processes and components leading to pharmacologic resistance to selective inhibitors.

Role of Wnt/β-Catenin Signaling in Colorectal Cancer {#sec1}
====================================================

β-Catenin Turnover Regulation {#sec1.1}
-----------------------------

Since the critical role of Wnt/β-catenin signaling in the etiology of CRC has been established, many studies have been conducted to identify key molecular players that could represent concrete targets for CRC chemoprevention and therapy.

In the inactive state, β-catenin levels are kept stably low through the dynamic activity of a protein complex known as the destruction complex or degradosome.[@bib9] This complex includes casein kinase 1α, glycogen synthase kinase 3 (GSK3), Axis inhibition protein 1, adenomatous polyposis coli (APC), protein phosphatase 2A, and the E3-ubiquitin ligase β-transducin repeats--containing protein.[@bib9], [@bib10], [@bib11], [@bib12], [@bib13] APC and Axis inhibition protein 1 function as scaffold proteins in the destruction complex, while casein kinase Iα and GSK3 are the main serine/threonine kinases involved in β-catenin phosphorylation.[@bib14] β-transducin repeats--containing protein mediates the ubiquitination of phosphorylated β-catenin and targets it for degradation by the proteasome machinery.[@bib15]^,^[@bib16] It is noteworthy that Axis inhibition protein 1 has been proposed as the rate-limiting factor for the degradosome assembly because its endogenous levels are finely regulated and kept low in the absence of Wnt stimulation.[@bib17]

Wnt ligands are active molecules that bind the 7-transmembrane receptor frizzled (FZD) family and the co-receptors low-density lipoprotein receptors 5 and 6 (LRP5/6).[@bib18], [@bib19], [@bib20], [@bib21] The formation of the ligand-receptor complex Wnt-FZD-LRP5/6 and the recruitment of the adaptor dishevelled (DVL) by FZD lead to LRP6 phosphorylation, Axis inhibition protein 1 translocation to the plasma membrane, its association with LRP6, and the dissociation of GSK3 from Axis inhibition protein 1 and APC with consequent dephosphorylation and stabilization of β-catenin.[@bib22]^,^[@bib23] These events cause the assembly of the signalosome, a multiprotein complex able of transducing Wnt signals, as well as the degradosome disassembly with consequent cytosolic β-catenin accumulation and nuclear translocation. Finally, nuclear β-catenin acts as a transcriptional co-activator interacting with T-cell transcription factor,[@bib24] or lymphoid enhancer factor,[@bib25] and inducing the transcription of target genes, including *AXIN2*,[@bib26] *c-MYC*,[@bib27] *CCND1*,[@bib28]^,^[@bib29] thus promoting cell proliferation and activation of oncogenic mechanisms.

Two main critical steps have been proposed to be responsible for the impairment of β-catenin degradation on Wnt stimulation, attributable to the inhibition of β-catenin phosphorylation or ubiquitination, respectively. Despite inhibition of β-catenin ubiquitination showing effects on the prevention of β-catenin degradation,[@bib30] most of the evidence supports the concept that the inhibition of β-catenin phosphorylation and the disassembly of the β-catenin destruction complex represent the crucial event for Wnt/β-catenin pathway activation. In particular, by studying the kinetics of β-catenin turnover at the steady-state level, Hernández et al[@bib31] showed that in the early phases after Wnt stimulation, the reduced levels of GSK3β-mediated β-catenin phosphorylation are responsible for β-catenin degradation inhibition, while a subsequent recovery of β-catenin phosphorylation would restore its degradation. Thus, according to this model, inhibition of β-catenin phosphorylation leads to β-catenin accumulation during Wnt stimulation.

Moreover, in the early phases after Wnt stimulation, Axis inhibition protein 1 protein stability is increased, thus enhancing the signalosome assembly and Wnt/β-catenin signaling initiation.[@bib32] On the other hand, on long-term Wnt stimulation, adenosine diphosphate--ribosylation by poly (adenosine diphosphate--ribose) polymerase enzyme tankyrase (TNKS) triggers Axis inhibition protein 1 proteolysis and degradation, resulting in the dissociation of the β-catenin destruction complex and sustained Wnt/β-catenin signaling activation.[@bib32] Thus, Axis inhibition protein 1 also functions as a fundamental switch for controlling both Wnt/β-catenin cascade activation and inhibition.

More comprehensive results about the mechanisms underlying Wnt/β-catenin signaling regulation and the dynamics of the β-catenin destruction complexes under the presence of Wnt signals have been described recently.[@bib33] Indeed, under Wnt stimulation, a fraction of the β-catenin destruction complexes is disassembled with a consequent initial accumulation of cytosolic β-catenin. At the same time, a portion of functional complexes do persist, capable of progressively restoring β-catenin phosphorylation and degradation rates.[@bib33]

Moreover, emerging evidence has shown that ring finger protein 43 (RNF43), the transmembrane E3 ubiquitin ligase zinc and ring finger 3 (ZNRF3) and DVL play a critical role in controlling extrinsic Wnt/β-catenin pathway activation by regulating the levels of Wnt receptors on the cellular membrane. Indeed, RNF43 and ZNRF3, promoting the internalization and the subsequent degradation of Wnt receptors FZD and LRP6, act as crucial negative regulators of the signaling.[@bib34]^,^[@bib35] Importantly, recent data have shown that DVL is required not only for Wnt/β-catenin signaling initiation but also for RNF43 and ZNRF3-mediated degradation of FZD and LRP6.[@bib36] In contrast, R-spondin, by inhibiting ZNRF3, operates as a Wnt/β-catenin signaling enhancer.[@bib35]

In addition, an interaction between Hippo and the Wnt/β-catenin signaling pathway has been described. However, the literature evidence still is quite controversial and the mechanisms underlying this crosstalk are under investigation. Indeed, although some studies described the Hippo signaling transducers Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif as components of the degradosome and transcriptional co-activators of β-catenin,[@bib37] other reports have indicated a possible involvement of the Hippo cascade in noncanonical Wnt signaling, showing that it acts as an inhibitor of the canonical Wnt signaling.[@bib38]^,^[@bib39] Moreover, APC has been described as a dual upstream regulator of both Hippo YAP and β-catenin pathways, which independently contribute to the intestinal tumorigenesis in the absence of functional APC,[@bib40] although another study showed that Wnt/β-catenin signaling directly regulates YAP expression through the β-catenin/T-cell transcription factor 4 transcriptional complex.[@bib41]

Overall, these extensive findings suggest that the regulation of this pathway is more complex than previously thought, and probably many mechanisms still need to be clarified.

Mutations in Wnt/β-Catenin Signaling Components {#sec1.2}
-----------------------------------------------

Genetic alterations in the Wnt/β-catenin pathway components, frequently observed in CRC, lead to the intrinsic aberrant canonical Wnt/β-catenin signaling activation. Inactivating germ-line mutations in the *APC* gene, encoding for the core scaffold element of the β-catenin destruction complex, are causative for the development of the rare hereditary CRC-predisposing syndrome familial adenomatous polyposis (FAP),[@bib42]^,^[@bib43] while somatic mutations in the *APC* gene constitute the most frequent initiating event in sporadic CRC (approximately 80%--90% of cases).[@bib44] Recent data have shown that APC regulates β-catenin levels, also acting as a modulator of the Wnt receptor LRP6.[@bib45]^,^[@bib46] Indeed, genetic alterations in the *APC* gene induce an autoassembly of the signalosome in the absence of Wnt ligands, thus resulting in uncontrolled pathway activation. Importantly, these new relevant data have raised the possibility of counteracting the functional effects induced by APC loss through the modulation of the upstream receptors.

Activating point mutations of the *β-catenin* encoding gene *CTNNB1* have been observed in a small percentage of CRC cases with wild-type *APC*, [@bib47] while somatic mutations in *AXIN2* mainly have been associated with mismatch repair--deficient CRC cases.[@bib48] Somatic *AXIN1* mutations, resulting in loss of function, also are found at low frequency in colorectal adenomas and CRC.[@bib49]^,^[@bib50] Finally, further causative alterations have been described in *RNF43*, *ZNRF3*, and *TCF4* genes. [@bib35]^,^[@bib51]^,^[@bib52]

The mTOR Pathway in CRC {#sec2}
=======================

PI3K/AKT/mTORC1 Axis {#sec2.1}
--------------------

mTOR is a serine/threonine protein kinase made of 2 multiprotein complexes: mTORC1 and mTORC2.[@bib53] Mammalian lethal with SEC13 protein 8 (mLST8) (also known as G Protein beta Subunit-like),[@bib54] DEP domain-containing mTOR-interacting protein (DEPTOR),[@bib55] and the Tel-2 interacting protein 1/Telomere maintenance 2 factors[@bib56] are common to both protein complexes. Regulatory-associated protein of mTOR[@bib57] and Proline-Rich AKT Substrate of 40 KDa[@bib58] are distinctive of the mTORC1 complex, while Rapamycin-insensitive companion of mTOR,[@bib59] mammalian Stress-activated protein kinase-interacting protein 1,[@bib60] and Protein observed with RICTOR 1/2[@bib61] belong to the mTORC2 complex. The 2 complexes act through different mechanisms and show a distinct sensitivity to stimuli, in particular to rapamycin, which is higher for mTORC1.[@bib62] Although the mTORC2 function still is not completely characterized, mTORC1 has been largely described.[@bib6] mTORC1 is activated on different stimuli, such as growth factors, nutrients, cellular stress, hypoxia, and DNA damage.[@bib6] The heterodimer complex constituted by tuberous sclerosis (TSC)1 and TSC2 plays a key role in the upstream regulation of the pathway and functions as a bridge to flow activating signals and molecules onto mTORC1. The TSC1/TSC2 complex works as a guanosine triphosphatase (GTPase) activating protein for Ras homolog enriched in brain (Rheb), a GTPase belonging to the Ras family.[@bib63] Rheb-GTP functions as a potent inducer of mTORC1 kinase activity. The TSC1/TSC2 complex, promoting the conversion from Rheb-GTP to Rheb--guanosine diphosphate, acts as a negative regulator of mTORC1 signaling.[@bib64]

Although the mTORC1 cascade is induced through different mechanisms, the main activation route in response to mitogenic stimuli involves the upstream regulators PI3K and AKT.[@bib65] PI3K induces AKT by promoting the conversion of phosphatidylinositol (3,4)-bisphosphate to phosphatidylinositol (3,4,5)-trisphosphate, and triggering AKT phosphorylation at Thr308 via 3'phosphoinositide-dependent kinase 1.[@bib66] This event leads to mTORC1 activation by AKT-mediated phosphorylation and the consequent inactivation of Proline-Rich AKT Substrate of 40 KDa (PRAS40)[@bib58] and TSC2.[@bib67]^,^[@bib68] Moreover, AKT also acts through mTORC1 phosphorylation at Ser2448.[@bib69] Once activated, mTORC1 mediates the phosphorylation of 2 main downstream targets: eukaryotic translation initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), and p70S6 ribosomal kinase 1 (S6 Kinase 1 \[S6K1\] or p70S6 ribosomal kinase 1). Phosphorylated 4E-BP1 dissociates from the cap-binding protein eIF4E, thus promoting messenger RNA translation.[@bib70]^,^[@bib71] In addition, activation of S6K1 protein leads to ribosomal protein S6 phosphorylation and consequent induction of translation initiation and elongation.[@bib72]

Genetic Alterations in the PI3K/AKT/mTORC1 Pathway {#sec2.2}
--------------------------------------------------

The involvement of the mTORC1 pathway in cancer onset and promotion has been widely described. The aberrant activation of this pathway frequently depends on genetic alterations in upstream regulators rather than in *mTOR* genes. Gain-of-function mutations in the *PIK3CA* gene have been described in 12%--32% of CRC patients and have been associated with proximal CRC.[@bib73], [@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79] Moreover, somatic mutations in components of the PI3K/AKT/mTORC1 pathway have been observed frequently in Lynch syndrome cases.[@bib80] Inactivating mutations or loss of heterozygosis in the *PTEN* gene, a negative regulator of PI3K activity, also have been found, particularly in tumors with microsatellite instability.[@bib79]^,^[@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86] *PTEN* epigenetic silencing represents an additional mechanism for PI3K activity regulation in CRC.[@bib87] Furthermore, somatic mutations in the *STK11/LKB1* gene, which encode for an mTORC1 repressor,[@bib88] have been observed in a small percentage of sporadic CRC cases.[@bib89]^,^[@bib90] Finally, *AKT* mutations are a rare occurrence in CRC.[@bib91]

PI3K/AKT/mTORC1 Signaling in Intestinal Tumorigenesis Driven by *Apc* Loss {#sec3}
==========================================================================

The involvement of PI3K/AKT/mTORC1 signaling in the progression of *Apc*-driven CRC has been shown largely in murine models. Treatment with the mTORC1 inhibitor everolimus was found to reduce tumor burden in the *Apc*^*Δ716*^ mouse model of FAP that showed induced mTORC1 signaling in the intestinal polyps.[@bib92] Similar findings have been obtained in the *Apc*^Min/+^ mouse model of FAP,[@bib93]^,^[@bib94] and in the *Apc* conditional knock-out mouse model with treatment with rapamycin.[@bib95] It should be noted that both β-catenin--dependent and β-catenin--independent mechanisms have been described to explain mTORC1 induction with Wnt pathway activation.[@bib92]^,^[@bib96]

Subsequent studies further clarified the involvement of mTORC1 signaling upon *Apc* inactivation. Indeed, although mTORC1 activation is crucial to ensure the survival and proliferation of murine enterocytes upon *Apc* gene deletion, its inhibition has no relevant effects on the intestines of *Apc* wild-type mice.[@bib97] This study described important mechanisms linking mTORC1 activation to the intestinal tumorigenesis driven by *Apc* loss. Upon *Apc* gene deletion, activated mTORC1 enhances the elongation translation rate by inhibiting the elongation factor 2 kinase (eEF2K) via S6K and activating the eEF2. Importantly, this mechanism involving the mTORC1-S6K-eEF2K-eEF2 axis seems crucial to sustain the growth and expansion of *Apc*-deficient enterocytes.[@bib97] Furthermore, the synergic effect of the Wnt/β-catenin and PI3K/AKT/mTORC1 pathways on the development of colonic lesions was shown in another study by crossing the *Apc*^Min/+^ and FC PIK3ca∗ mice. In this model, characterized by a germ-line mutation in the *Apc* gene and constitutive activation of PI3K in the intestine, the simultaneous activation of both pathways boosted tumor initiation and promotion.[@bib98]

Recently, Brandt et al[@bib99] showed that although mTORC1 inhibition could represent an effective preventive strategy against *Apc* mutant CRC, it could promote carcinogenesis in long-standing inflammatory bowel diseases. Indeed, in a setting of chronic inflammation, mTORC1 signaling plays a critical protective role by promoting intestinal regeneration upon injury. Interestingly, given the existing link between protein intake and mTORC1 activation, the investigators have proposed that it would be possible to affect colonic tumor progression by adjusting the dietary protein intake, depending on the underlying mechanisms of CRC development (ie, low-protein intake in Wnt-sustained tumors or high-protein intake in a condition of persistent inflammation).[@bib99] This evidence suggests a new possible scenario in the prevention of CRC, coupling a pharmacologic approach with dietary strategies that could increase the effectiveness of targeted drugs substantially.

Common Effectors and Linking Elements Between Wnt/β-Catenin and PI3K/AKT/mTORC1 Pathways {#sec4}
========================================================================================

GSK3β {#sec4.1}
-----

Wnt/β-catenin and PI3K/AKT/mTORC1 pathways share some effectors critically involved in both signaling pathways. GSK3β represents a common key element, which independently participates in both signaling cascades regulating different cellular processes. GSK3 kinase is constitutively active and is regulated negatively through different mechanisms. Distinct intracellular pools of GSK3β have been implicated in the regulation of Wnt/β-catenin and PI3K/AKT/mTORC1.[@bib100] The activation of both signaling pathways results in the inhibition of GSK3β activity, although via different upstream events. The regulation of GSK3β activity during Wnt signaling occurs mainly through protein--protein interactions and intracellular sequestration.[@bib100] In the Wnt/β-catenin pathway, a fraction of AXIN-bound GSK3β has an important role in controlling β-catenin degradation, through the regulation of β-catenin phosphorylation.[@bib101] In particular, the GSK3β interaction with the scaffolding protein AXIN is crucial to allow an efficient GSK3β-mediated phosphorylation of β-catenin.[@bib10] Importantly, APC also regulates GSK3β. Indeed, the APC dissociation from AXIN, which is induced rapidly on Wnt stimulation, weakens GSK3β activity, with consequent β-catenin stabilization.[@bib102] In addition, the GSK3β-mediated LRP6 phosphorylation, which occurs on Wnt stimulation, leads to GSK3β inhibition.[@bib103]

GSK3β also interacts with the PI3K/AKT/mTORC1 pathway through different mechanisms. [@bib96]^,^[@bib102]^,^[@bib104] Upon PI3K activation, phosphorylated AKT is able to inhibit GSK3β kinase activity by inducing its phosphorylation at Ser9.[@bib105]^,^[@bib106] In addition, in specific circumstances, such as reduced AKT activation, GSK3β can be phosphorylated and inactivated by S6K.[@bib107] Importantly, much evidence has shown that GSK3β inhibition (induced upon Wnt stimulation) does not occur through AKT-mediated phosphorylation at Ser9.[@bib108] Thus, AKT activation has no direct effects on the Wnt/β-catenin pathway.[@bib109]^,^[@bib110] However, as suggested by Ding et al,[@bib109] it is possible that in conditions of AKT hyperactivation and active canonical Wnt signaling, the simultaneous inhibition of GSK3β activity induced by the 2 signaling pathways may result in enhanced β-catenin accumulation. Moreover, *APC* loss, leading to GSK3β dysregulation and reduction of its kinasic activity, has been associated with mTORC1 activation with a mechanism independent from β-catenin accumulation.[@bib102] Thus, APC inhibition represents a critical event for the simultaneous induction of both β-catenin and mTORC1 signaling through independent downstream mechanisms sharing the upstream inhibition of GSK3β.[@bib102]

mTORC1 inhibition promotes GSK3β nuclear translocation,[@bib111] and, importantly, GSK3β expression seems crucial for cancer cell responsiveness to mTOR inhibitors.[@bib112] A new mechanism explaining the relationship between GSK3β and mTORC1 has been proposed recently.[@bib113]^,^[@bib114] The investigators showed that GSK3β nuclear translocation induced by rapamycin was associated with increased phosphorylation of the nuclear proteins Forkhead Box K1 and General Transcription Factor IIF Subunit 1, slowing down cell proliferation.[@bib113]^,^[@bib114]

Although the role of the PI3K/AKT/mTORC1 pathway in the modulation of translation is widely described,[@bib115] the involvement of Wnt/β-catenin signaling in this process is poorly characterized. Preclinical studies have shown that both intrinsic and extrinsic Wnt pathway activation, leading to S6K and 4E-BP1 phosphorylation, may affect the protein synthesis turning on the mTORC1 cascade. Importantly, the Wnt-driven mTORC1 signaling activation seems to be independent from β-catenin and mediated by an axis involving APC-AXIN-GSK3β and TSC2 ([Figure 1](#fig1){ref-type="fig"}*A*).[@bib96]Figure 1**Main mechanisms of Wnt/β-catenin and PI3K/AKT/mTORC1 pathway interconnections.** (*A*) The Wnt/β-catenin pathway modulates transcription through β-catenin and translation via mTORC1 regulating GSK3β activity.[@bib96] (*Bi*) mTORC1 inhibition by the rapalog everolimus induces Wnt/β-catenin signaling activation by increasing the expression of FZD receptor levels with a mechanism dependent on DVL. (*Bii*) Activated mTORC1 promotes the association between DVL and the clathrin Adaptor protein 2 (AP-2) adaptor with a consequent reduction of FZD expression levels, with a negative regulation of Wnt/β-catenin signaling.[@bib116] (*C*) Wnt/β-catenin signaling switches off the mTORC1 cascade by inducing its negative regulator DEPTOR.[@bib117] (*D*) Inhibited PI3K/AKT/mTORC1 pathway leads to increased eIF4E phosphorylation via MNK.[@bib124] Phosphorylated eIF4E is associated with β-catenin nuclear translocation and signaling activation.[@bib127] β-CAT, β-catenin; β-TRCP, Beta-transducin repeat containing E3 ubiquitin protein ligase.

FZD, DVL, and Deptor {#sec4.2}
--------------------

Recently, Zeng et al[@bib116] showed that mTORC1 negatively regulates Wnt/β-catenin signaling by modulating the extrinsic Wnt response both ex vivo and in vivo, and showed that mTORC1 would affect the expression of the Wnt receptor FZD with a mechanism dependent on the Wnt-positive regulator DVL ([Figure 1](#fig1){ref-type="fig"}*B*). Importantly, the mTORC1-driven inhibition of Wnt/β-catenin signaling resulted in a compromised stem cell function in intestinal organoids, highlighting the importance of mutual regulation for intestinal homeostasis maintenance.[@bib116] The role of DVL in the regulation of Wnt receptors LRP6 and FZD has been shown previously in vitro through a genome editing approach. Although DVL is critically involved in the signalosome assembly, it also modulates the cellular turnover of Wnt receptors, being implicated in a negative feedback loop controlled by ZNRF3 and RNF43.[@bib36]

Wang et al[@bib117] recently described a mechanism linking the Wnt/β-catenin and mTORC1 pathways, showing that Wnt/β-catenin signaling induction, up-regulating the mTORC1-negative regulator DEPTOR, leads to DEPTOR-mediated mTORC1 suppression ([Figure 1](#fig1){ref-type="fig"}*C*).

eIF4E {#sec4.3}
-----

An additional connection between the 2 signaling pathways involves the translation initiation factor eIF4E.[@bib118] The up-regulation of eIF4E has been described in multiple cancers,[@bib119] including CRC.[@bib120]^,^[@bib121] The main oncogenic mechanism attributed to eIF4E is related to promoting the translation of genes critically involved in the malignant transformation of epithelial cells.[@bib122] The oncogenic activity of eIF4E is enhanced through its phosphorylation at Ser209, promoted by Mitogen-activated Protein kinase (MAPK) interacting kinases (MNK) 1 and MNK2.[@bib123] It is known that mTORC1 inhibition by rapamycin leads to increased eIF4E phosphorylation and activation via a MNK1- and PI3K-dependent mechanism in different types of cancer cells, including CRC cell lines.[@bib124] It should be noted that this feedback mechanism could be counteracted by using PI3K inhibitors, as shown in human lung cancer cells.[@bib125] Importantly, eIF4E phosphorylation also has been associated with Wnt/β-catenin signaling activation by promoting β-catenin nuclear translocation in different cancer settings ([Figure 1](#fig1){ref-type="fig"}*D*).[@bib126]^,^[@bib127]

Wnt/β-Catenin and PI3K/AKT/mTORC1 Pathways as Drivers of CRC Resistance to Treatment {#sec5}
====================================================================================

Target cancer therapy resistance generally is driven by the development of additional mutations in downstream effectors of the same targeted pathway or activation of alternative signaling pathways as compensatory mechanisms.[@bib7]

Rapalogs and Dual PI3K/mTOR Inhibitors {#sec5.1}
--------------------------------------

Everolimus and temsirolimus are 2 mTORC1 inhibitors whose efficacy have been evaluated in phase II clinical trials in metastatic CRC patients.[@bib128]^,^[@bib129] However, a small retrospective analysis of tumors with activating *PIK3CA* mutations showed that treatment with the mTORC1 inhibitor everolimus had no relevant effect.[@bib130] In addition, it has been shown that mTORC1/2 inhibition could restore sensitivity to everolimus in *PIK3CA* mutant CRC in preclinical models.[@bib130] PKI-587,[@bib131] XL765,[@bib132] BEZ235,[@bib133] and LY3023414[@bib134] are dual PI3K/mTOR inhibitors that have completed phase I clinical trials in patients with advanced solid tumors, including CRC. It has been shown that the Wnt/β-catenin pathway activation induces resistance to dual PI3K/mTOR inhibitor PKI-587 in *PIK3CA* mutant CRC cells, while GSK3β inactivation restored the sensitivity to PKI-587.[@bib135] However, these counterintuitive results are not in agreement with the general view supporting the negative regulator role of GSK3β in the Wnt/β-catenin pathway, and contradict robust literature data showing that GSK3β inhibitors activate Wnt/β-catenin signaling. Importantly, endogenous levels of GSK3β are crucial in determining the sensitivity to mTORC1 inhibitors in CRC. Indeed, GSK3β down-regulation has been associated with mTORC1 inhibitor resistance.[@bib136] Moreover, high levels of the GSK3β nuclear exporter Frequently rearranged in advanced T-cell lymphomas 1/2, which interferes with the cytostatic effects of rapamycin, might be relevant to predict the response to rapalogs as shown in lung and breast cancer cell lines ([Figure 2](#fig2){ref-type="fig"}*A*).[@bib114] Recently, Foley et al[@bib137] showed that turning off both PI3K and mTOR by using the inhibitors BEZ235 and LY3023414 may represent an effective therapeutic strategy in CRC carrying concomitant *APC* and *PIK3CA* mutations.Figure 2**Resistance mechanisms to rapamycin and TNKSi.** (*Ai*) mTORC1 inhibition promotes GSK3β nuclear translocation. Nuclear GSK3β mediates rapamycin-induced cytostasis by increasing the phosphorylation of Forkhead Box K1 and General Transcription Factor IIF Subunit 1. (*Aii*) In conditions of high cellular levels of the GSK3β nuclear exporter Frequently rearranged in advanced T-cell lymphomas 1/2 (FRAT 1/2), upon mTORC1 inhibition, nuclear GSK3β levels are not sufficient to induce cytostasis leading to rapamycin resistance.[@bib113]^,^[@bib114] (*Bi*) mTORC1 induction is associated with TNKSi resistance and persistent Wnt/β-catenin signaling activation. (*Bii*) mTORC1 activity reduction by temsirolimus restores the sensitivity to TNKSi, leading to Wnt/β-catenin down-regulation.[@bib144] β-CAT, β-catenin; β-TRCP, Beta-transducin repeat containing E3 ubiquitin protein ligase; CKI, Casein Kinase I.

Tankyrase Inhibitors {#sec5.2}
--------------------

Tankyrase inhibitors (TNKSi) are small molecules that induce Axis inhibition protein 1/2 stabilization, abrogating Wnt/β-catenin signaling.[@bib4] Several TNKSi, including XAV939,[@bib138] IWR-1,[@bib139] JW74,[@bib140] and G007-LK,[@bib141] have been shown to impair Wnt/β-catenin signaling in vitro or in mouse models of CRC. However, Wnt/β-catenin inhibition induced by TNKSi has been associated with intestinal cytotoxicity and CRC cell lines have shown heterogeneous sensitivity to TNKSi.[@bib142]^,^[@bib143] Mashima et al,[@bib144] by using the TNKSi-resistant cell line 320-IWR, provided evidence of mTORC1 activation as a resistance mechanism to TNKSi IWR-1 and G007-LK. Interestingly, inhibition of mTORC1 by temsirolimus restored sensitivity to TNKSi ([Figure 2](#fig2){ref-type="fig"}*B*). These data further show that mTORC1 activation might represent a survival mechanism used by cancer cells upon Wnt/β-catenin signaling inhibition. Recently, the combined effect of TNKSi inhibitor G007-LK, the PI3K inhibitor NVP-BKM120, and the epidermal growth factor receptor (EGFR) inhibitor erlotinib has been evaluated in CRC cell lines and xenografts. In both TNKSi-sensitive COLO320 DM and TNKSi-insensitive HCT-15 cell lines the combined inhibition of TNKSi, PI3K, and EGFR was able to reduce cell growth, as well as tumor size in vivo, by acting on multiple cancer-related pathways including Wnt/β-catenin, AKT/mTOR, EGFR, and Rat Sarcoma (RAS) signaling, with different effects depending on the genetic profile of the studied cell lines.[@bib145]

Forkhead box O3a (FOXO3a) is a transcription factor that acts as a tumor suppressor, inducing cell-cycle arrest and apoptosis.[@bib146] Phosphorylation of FOXO3a by AKT induces its sequestration into the cytoplasm and inhibition of its transcriptional activity while PI3K or AKT inhibitors relocate FOXO3a into the nucleus, restoring its tumor-suppressor role. Importantly, high levels of nuclear β-catenin confer resistance to FOXO3a-induced apoptosis in metastatic CRC patient--derived cells treated with PI3K/AKT inhibitors.[@bib147] Notably, TNKSi XAV-939 reverted this resistance, sensitizing cells to FOXO3a-induced apoptosis.[@bib147] In addition, CRC patient--derived cells with high levels of nuclear β-catenin show reduced apoptosis upon treatment with the AKT or PI3K inhibitors API2 or NVP-BKM120.[@bib148] As suggested by the investigators, these data support the concept that Wnt/β-catenin hyperactivation leads to pharmacologic resistance to PI3K and AKT inhibitors in CRC. Importantly, the association of the TNKSi NVP-TNKS656 (a derivative of XAV939) with PI3K and AKT inhibitors improve the response to treatment both in vitro and in vivo, in particular in the presence of high nuclear β-catenin and FOXO3a levels.[@bib148]

Taken together, these findings indicate that a valid strategy to overcome resistance to PI3K/AKT/mTOR inhibitors could be combining these inhibitors with TNKSi to block the Wnt/β-catenin pathway.

Targeting RAS/Rapidly Accelerated Fibrosarcoma/Mitogen-Activated Protein Kinase Kinase/Extracellular Regulated Kinase {#sec5.3}
---------------------------------------------------------------------------------------------------------------------

EGFR is upstream of both mitogen-activated protein kinase and PI3K/AKT pathways. Much evidence has shown that, after the administration of the anti-EGFR therapies cetuximab or panitumumab, CRC acquires drug resistance through the activation of the downstream extracellular regulated kinase 1/2 signaling as a consequence of mutations in *KRAS*, *NRAS*, and Mitogen-activated protein kinase kinase (MAPKK or MEK) (MEK)1/2.[@bib149] MEK is downstream of Kirsten rat sarcoma 2 viral oncogene homolog in the RAS/Rapidly Accelerated Fibrosarcoma/MEK/extracellular regulated kinase pathway and inhibition of MEK blocks signal transduction independently from the upstream mutation. Moreover, it is known that *PIK3CA* mutations confer resistance to MEK inhibitors in *KRAS* mutant cancers.[@bib150] Recently, a study showed that β-catenin was responsible for the resistance of *PIK3CA* mutated tumors to MEK inhibitors.[@bib151] Notably, pharmacologic inhibition of β-catenin with TNKSi NVP-TNKS656 can resensitize *PIK3CA* mutant cells to MEK inhibitors.[@bib151]

Porcupine Inhibitors {#sec6}
====================

A further mechanism that turns off the Wnt/β-catenin signaling is through the impairment of the enzymatic activity of Porcupine (PORCN), which mediates the palmitoleation and subsequent secretion of Wnt ligands.[@bib152], [@bib153], [@bib154] Various PORCN inhibitors have been tested in preclinical models as a strategy against Wnt-driven cancers, some of which, including LGK974 or ETC-159, have been used in early phase clinical trials.[@bib155], [@bib156], [@bib157] However, as for the majority of Wnt inhibitors, PORCN inhibitors also impair intestinal homeostasis and are subjected to resistance.[@bib157] Interestingly, Axis inhibition protein 1 suppression recently has been described as a driver of resistance to the PORCN inhibitor LGK974 in CRC cell lines, carrying genomic rearrangements in the *RSPO3* gene.[@bib158] It should be noted that the combination of PORCN inhibitor ETC-159 with PI3K/mTOR inhibitors has shown a synergistic effect against tumor growth in pancreatic cancer cells with RNF43 mutations, as well as in vivo models, indicating that the dual blockage might be effective in CRC.[@bib159]

An overview of Wnt/β-catenin, rapalogs, and dual PI3K/mTOR inhibitors tested in clinical and preclinical CRC settings is shown in [Table 1](#tbl1){ref-type="table"}.Table 1Overview of Wnt/β-Catenin, Rapalogs, and Dual PI3K/mTOR Inhibitors Discussed in This ReviewInhibitorsTargetTested settingsFindingsReferencesRapamycinmTORC1Murine modelInhibition of intestinal neoplasia in *Apc* mutant models93,95EverolimusmTORC1Murine modelReduced tumor burden in the *Apc*^*Δ716*^ mouse model92EverolimusmTORC1CRC (phase II study)Limited efficacy in metastatic CRC128TemsirolimusmTORC1CRC (phase II study)Limited efficacy in *KRAS* mutant CRC129TemsirolimusmTORC1CRC cell linesReversed resistance to TNKSi144TAK228mTORC1/2Murine models and spheroidsOvercomes resistance to everolimus and induces response in *PIK3CA* mutant CRCs130PKI-587PI3K/mTORCSolid tumors (phase I study)Antitumor activity in patients resistant to conventional therapies131PKI-587PI3K/mTORCCRC cell linesResistance to PKI-587 in *PIK3CA* mutant CRC cells135XL765PI3K/mTORCSolid tumors (phase I study)Antitumor activity in patients resistant to conventional therapies132BEZ235PI3K/mTORCSolid tumors (phase I study)No effect in patients with advanced solid tumors133LY3023414PI3K/mTORCSolid tumors (phase I study)Efficacy in patients with advanced solid tumors134LY3023414PI3K/mTORCMurine models and spheroidsPotential treatment strategy in *PIK3CA* mutant CRCs137XAV939TNKSCell lines, patient-derived cells, murine modelsReversed resistance in patient-derived primary cultures and in corresponding xenograft tumors in mice147JW74TNKSCell lines and murine modelsDecreased cell growth in CRC xenograft and reduced polyp formation in *Apc*^Min**/+**^ mice140G007-LKTNKSCell lines and murine modelsReduced CRC cell line growth; tumor growth inhibition in *Apc* mutant CRC xenograft and genetically engineered CRC models141G007-LKTNKSCell lines and murine modelsEnhanced effect of PI3K (BKM120) and EGFR (erlotinib) inhibition in CRC cells and reduced growth of CRC xenografts in vivo145NVP-TNKS656TNKSCell lines, patient-derived cells, murine modelsOvercomes resistance to PI3K or AKT inhibitors in CRC patient-derived sphere cultures and represses tumor growth in CRC-PDX models148NVP-TNKS656TNKSCell lines and murine modelsOvercomes resistance to MEK inhibitors in CRC with *KRAS* and *PIK3CA* mutations151ETC-159PORCNMurine modelsEffective for treatment of *RSPO* translocation in CRC xenografts156LGK974PORCNCell lines and murine modelsLoss of AXIN1 mediates resistance to LGK974 in CRC cells carrying RSPO3 fusions158[^1]

Conclusions {#sec7}
===========

The interconnection between the Wnt/β-catenin and PI3K/AKT/mTORC1 pathways has been shown widely in different cancer settings, including CRC. Most of the studies elucidating the relationship between these pathways have been conducted in preclinical models. As discussed in this review, there are many connecting elements between these 2 pathways capable of interfering with key processes regulating the β-catenin turnover: (1) in particular, the regulation of β-catenin phosphorylation mediated by GSK3β and the degradosome assembly/disassembly; (2) the modulation of the Wnt receptor levels (extrinsic Wnt activation) in which DVL has a crucial role; (3) mechanisms affecting the β-catenin nuclear translocation, which involves many components including eIF4E; and (4) the regulation of the downstream effectors of the PI3K/AKT/mTORC1 pathway mediated by GSK3β. Moreover, clinical data in patients with advanced disease showed increased resistance to targeted therapies, highlighting the relevance of this interaction in predicting patient response. In this context, GSK3β levels seem crucial for predicting the response to mTORC1 inhibitors. In addition, defined cancer and precancerous subsets could benefit from the combination of PI3K/mTORC1 inhibitors with TNKSi. In particular, simultaneous inhibition of both the Wnt/β-catenin and PI3K/AKT/mTORC1 pathways may represent a valid chemopreventive strategy in FAP, in which the proliferative boost and oncogenic transformation of intestinal epithelial cells is supported by Wnt/β-catenin signaling overactivation. In conclusion, it is important to note 2 relevant concepts for future studies: the interdependence, which characterizes these pathways, constitutes a critical factor, for developing new drugs against CRC progression; and the dynamics that characterize these 2 signaling pathways, in the context of colorectal carcinogenesis, should be evaluated, taking into account the response and the fine regulation processes that distinguish these pathways. Future studies on this topic in human beings will be indispensable to better define unsolved mechanisms in this challenging scenario and to establish the translational impact of these crosstalk mechanisms.
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